新型药物组合伊沙匹隆与卡培他滨对三阴性转移性乳腺癌的持久控制——病例报告
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
作者信息
Vrdoljak Eduard, Mise Branka Petrić, Lukić Blanka, Curić Zvonimir, Bosković Lidija, Tica Ivana
机构信息
Center of Oncology, University Hospital Split, Split, Croatia.
出版信息
Onkologie. 2010;33(1-2):53-6. doi: 10.1159/000264615. Epub 2010 Jan 5.
BACKGROUND
The optimal duration of ixabepilone and capecitabine chemotherapy combination is currently not known and will most likely be patient-specific based on efficacy, toxicity, quality of life, and patient preference.
CASE REPORT
We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes. Partial remission was achieved, and acceptable toxicity was observed.
CONCLUSIONS
This report adds to the pool of knowledge regarding the use of this important new metastatic breast cancer regimen, especially with respect to the optimal duration of its use.
背景
目前尚不清楚伊沙匹隆与卡培他滨联合化疗的最佳疗程，很可能需根据疗效、毒性、生活质量和患者偏好因人而异。
病例报告
我们报告了1例三阴性转移性乳腺癌患者接受伊沙匹隆与卡培他滨化疗（42个周期）的疗程极长的情况，该患者既往接受过蒽环类药物和紫杉烷类药物治疗。实现了部分缓解，并观察到可接受的毒性。
结论
本报告增加了关于这种重要的新转移性乳腺癌治疗方案应用的知识储备，尤其是在其使用的最佳疗程方面。
Zotero 插件